These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20536646)

  • 41. Ustekinumab.
    Weber J; Keam SJ
    BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T helper 1 to T helper 2 shift in cytokine expression: an autoregulatory process in superantigen-associated psoriasis progression?
    Jain S; Kaur IR; Das S; Bhattacharya SN; Singh A
    J Med Microbiol; 2009 Feb; 58(Pt 2):180-184. PubMed ID: 19141734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
    Krueger GG; Langley RG; Leonardi C; Yeilding N; Guzzo C; Wang Y; Dooley LT; Lebwohl M;
    N Engl J Med; 2007 Feb; 356(6):580-92. PubMed ID: 17287478
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV; Exter BP; Steinberg M; Jarvis CI
    Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease.
    Shear NH; Prinz J; Papp K; Langley RG; Gulliver WP
    J Cutan Med Surg; 2008 Dec; 12 Suppl 1():S1-10. PubMed ID: 19886505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD4 T-helper cell cytokine phenotypes and antibody response following tetanus toxoid booster immunization.
    Livingston KA; Jiang X; Stephensen CB
    J Immunol Methods; 2013 Apr; 390(1-2):18-29. PubMed ID: 23318779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab.
    Wcisło-Dziadecka DL; Grabarek B; Kruszniewska-Rajs C; Gola JM; Simka K; Mazurek U
    Adv Clin Exp Med; 2020 Feb; 29(2):235-241. PubMed ID: 32125100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent treatment of chronic psoriasis and asthma with ustekinumab.
    Amarnani A; Rosenthal KS; Mercado JM; Brodell RT
    J Dermatolog Treat; 2014 Feb; 25(1):63-6. PubMed ID: 23469809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
    Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
    J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
    Reich K; Schenkel B; Zhao N; Szapary P; Augustin M; Bourcier M; Guenther L; Langley RG
    J Dermatolog Treat; 2011 Dec; 22(6):337-47. PubMed ID: 21034290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ustekinumab: a new option in psoriasis therapy.
    Chien AL; Elder JT; Ellis CN
    Drugs; 2009 Jun; 69(9):1141-52. PubMed ID: 19537833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
    Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tildrakizumab for treating psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
    Landells I; Marano C; Hsu MC; Li S; Zhu Y; Eichenfield LF; Hoeger PH; Menter A; Paller AS; Taieb A; Philipp S; Szapary P; Randazzo B
    J Am Acad Dermatol; 2015 Oct; 73(4):594-603. PubMed ID: 26259989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.